样式: 排序: IF: - GO 导出 标记为已读
-
The communication GAP between patients and clinicians and the importance of patient reported outcomes in Systemic Lupus Erythematosus Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-03-14 Elena Elefante, Alain Cornet, Jeanette Andersen, Amy Somers, Marta Mosca
Systemic Lupus Erythematosus (SLE) imposes a great burden on the lives of patients. Patients' and physicians' concerns about the disease diverge considerably. Physicians focus on controlling disease activity to prevent damage accrual, while patients focus on symptoms that impact on Health-Related Quality of Life (HRQoL). We explored the physicians' and patients' perspective and the potential role of
-
Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-03-13 Benjamin Cai, Ranjeny Thomas
Dendritic cells (DCs) are professional antigen-presenting cells and trigger downstream immune responses to antigen while integrating cellular pathogen and damage-associated molecular pattern (PAMP and DAMP) or immunomodulatory signals. In healthy individuals, resting and tolerogenic DCs draining skin and intestine facilitate expansion of regulatory T cells (Treg) to maintain peripheral antigen-specific
-
Problems with opioids - beyond misuse Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-03-01 Dorna Kheirabadi, Deeba Minhas, Rezvan Ghaderpanah, Daniel J. Clauw
The U.S. is grappling with an opioid epidemic, with millions of adults on long-term opioid therapy (LTOT). Although patients often report pain relief and improved daily function with opioids, research shows no significant differences in short-term outcomes between opioid and non-opioid users, as well as no long-term opioid benefits. This scoping review aims to identify lesser-known side effects of
-
Non-coding DNA variants for risk in lupus Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-29 Yutong Zhang, Guojun Hou, Nan Shen
Systemic Lupus Erythematosus (SLE) is a multifactorial autoimmune disease that arises from a dynamic interplay between genetics and environmental triggers. The advent of sophisticated genomics technology has catalyzed a shift in our understanding of disease etiology, spotlighting the pivotal role of non-coding DNA variants in SLE pathogenesis. In this review, we present a comprehensive examination
-
Cervicogenic headache – How to recognize and treat Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-22 Elcio Juliato Piovesan, Marco Antonio Takashi Utiumi, Débora Bevilaqua Grossi
Cervicogenic headache, described almost 100 years ago, only had its clinical awakening at the end of the century with the work of Professor Sjaastad. Its classic definition is the induction of trigeminal symptoms from cervical disorders, thanks to trigeminocervical convergence mechanisms. For this reason, it can manifest several features typical of migraine, leading to diagnostic errors. Classically
-
Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-22 Matteo Piga, Kostantinos Tselios, Luísa Viveiros, Elisabetta Chessa, Ana Neves, Murray Barry Urowitz, David Isenberg
Systemic lupus erythematosus (SLE) is a complex disease with an insidious clinical presentation. In up to half of the cases, SLE onset is characterized by clinical and serological manifestations that, although specific, are insufficient to fulfill the classification criteria. This condition, called incomplete SLE, could be as challenging as the definite and classifiable SLE and requires to be treated
-
“Fibromyalgia – are there any new approaches?” Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-13 José Eduardo Martinez, Izabela Guimarães
Approaching patients with fibromyalgia (FM) is challenging due to the limited availability of scientifically proven effective therapies. Review the treatments in use for FM and present new knowledge that could benefit these patients. Non-pharmacological interventions are recommended as the first line of treatment: aerobic exercise, cognitive behavioral therapy and patient education, all aimed at improving
-
Femoroacetabular impingement – What the rheumatologist needs to know Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-09 Aricia Jieqi Thirumaran, Nicholas J. Murphy, Kai Fu, David J. Hunter
Femoroacetabular impingement (FAI) syndrome is a common cause of hip and groin pain in young individuals. FAI syndrome is a triad of signs, symptoms, and imaging findings. Necessary but not sufficient for the diagnosis of FAI syndrome is the presence of cam and/or pincer morphology of the hip. However, pathological thresholds for cam and pincer morphologies are not well-established. Management of FAI
-
Practical approaches for clinicians in chronic pain management: Strategies and solutions Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-09 John A. Sturgeon, Corinne Cooley, Deeba Minhas
Effective management of chronic pain necessitates multidisciplinary approaches including medical treatment, physical therapy, lifestyle interventions, and behavioral or mental health therapy. Medical providers regularly report high levels of stress and challenge when treating patients with chronic pain, which recur in part due to improper education on contributors to pain and misalignment in patient
-
B cell activation and autoantibody production in autoimmune diseases Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-07 Wenbo Sun, Can Zhu, Yuxin Li, Xinfeng Wu, Xiaofei Shi, Wanli Liu
B cells are central players in the immune system, responsible for producing antibodies and modulating immune responses. This review explores the intricate relationship between aberrant B cell activation and the development of autoimmune diseases, emphasizing the essential role of B cells in these conditions. We also summarize B cell receptor signaling and Toll-like receptor signaling in B cell activation
-
Granzyme K+ CD8 T cells in autoimmunity Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2024-02-02 Anna Helena Jonsson
CD8 T cells expressing granzyme K are enriched in synovial tissue from patients with rheumatoid arthritis and in tissues affected by several other autoimmune diseases. The roles these cells play in autoimmune disease is under active investigation, and several recent studies have begun to shed light on this question. Putting this cell type into functional perspective is especially important given their
-
Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-26 Juan M. Mejia-Vilet, Tabitha Turner-Stokes, Frederic Houssiau, Brad H. Rovin
In the last few years, several studies have provided new evidence for the diagnosis, management, and follow-up of patients with lupus nephritis. Evidence showing dissociation between clinical and histological findings has prompted reevaluation of the role of the kidney biopsy as a tool for diagnosis and follow-up. In therapeutics, four immunosuppressive schemes now have supporting evidence for use
-
Editorial Board Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-20
Abstract not available
-
-
Editorial Board Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-11
Abstract not available
-
Index for PART A Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-11
Abstract not available
-
Index for PART B Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-11
Abstract not available
-
Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-05 Ioannis Parodis, Cristina Lanata, Dionysis Nikolopoulos, Ashira Blazer, Jinoos Yazdany
Health disparities in the prevalence and outcomes of systemic lupus erythematosus (SLE) are well documented across racial and ethnic groups. Similar to other chronic diseases, differences in disease severity among individuals with SLE are likely influenced by both genetic predisposition and multiple social determinants of health. However, research in SLE that jointly examines the genetic and environmental
-
Assessment of disease activity and damage in SLE: Are we there yet? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-02 Claudio Cruciani, Margherita Zen, Mariele Gatto, Eric Morand, Andrea Doria
Systemic Lupus Erythematosus is a systemic autoimmune disease characterized by a great heterogenicity in course and clinical manifestations. Although prognosis improved in the last decades of the 20th century, mortality remains higher than in the general population and uncontrolled disease activity and therapy-related adverse effects have been identified as major contributors to damage accrual and
-
Structural disease modification in axial spondyloarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-12-01 Brona Dinneen, Finbar O’Shea, Lianne Gensler
“Disease modification” in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease’s natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural
-
Pathophysiology and immunolgical basis of axial spondyloarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-28 Marleen G.H. van de Sande, Dirk Elewaut
Over the recent years the wider availability and application of state-of-the-art immunological technologies greatly advanced the insight into the mechanisms that play an important role in axial spondyloarthritis (axSpA) pathophysiology. This increased understanding has facilitated the development of novel treatments that target disease relevant pathways, hereby improving outcome for axSpA patients
-
Impact of sex and gender on axSpA diagnosis and outcomes Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-25 Samantha O. Kohn, Abeera Azam, Lauren E. Hamilton, Stephanie R. Harrison, Elizabeth R. Graef, Kristen J. Young, Helena Marzo-Ortega, Jean W. Liew
Axial spondyloarthritis (axSpA) was historically considered a disease of men, largely due to the recognition of a more severe, progressive phenotype, ankylosing spondylitis (AS; or radiographic axSpA, r-axSpA) aiding the clinical diagnosis [[1], [2]]. Data demonstrating the near equal prevalence of axSpA in women only started to emerge in the last decades, highlighting intrinsic differences in disease
-
Systemic lupus erythematosus and damage: What has changed over the past 20 years? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-22 Carolina Muñoz-Grajales, Esin Beste Yilmaz, Elisabet Svenungsson, Zahi Touma
The young age of onset and chronic/relapsing nature of systemic lupus erythematosus (SLE) make SLE patients prone to develop and accrue organ damage as a result of long-standing disease activity and side effects of treatment. There is a growing interest in objectifying damage and identifying its risk factors. Still, the lack of therapeutic alternatives has led to difficulties in avoiding immunosuppressives
-
Exploring osteoarthritis: Unraveling challenges, innovations, and hope for a better future Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-19 Mehmet Tuncay Duruöz
Abstract not available
-
Management of systemic lupus erythematosus: A new scenario Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-17 Georgia-Savina Moysidou, Dimitrios Mastrogiorgakis, Dimitrios Boumpas, George Bertsias
The introduction of targeted biological agents in systemic lupus erythematosus (SLE) has created a momentum for improving overall disease management and patients’ prognosis. To achieve this, a comprehensive strategy is required spanning the entire patient journey from diagnosis to prevention and management of late complications and comorbidities. In this review, we focus on four aspects that are closely
-
Advances in axial spondyloarthritis: Learning from the leaders Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-18 Sofia Ramiro, Nigil Haroon
Abstract not available
-
Systemic lupus erythematosus and glucocorticoids: A never-ending story? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-11 Diana Paredes-Ruiz, Guillermo Ruiz-Irastorza, Zahir Amoura
Glucocorticoids (GCs) continue to be essential agents for the management of systemic lupus erythematosus, since there are no other drugs able to active remission of active disease so rapidly. However, their potential for causing irreversible damage greatly limit their use. Fortunately, some strategies may help take advantage of their huge anti-inflammatory power while limiting GC-induced side effects
-
Clash of the titans: Current CT and CT-like imaging modalities in sacroiliitis in spondyloarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-11 Kelly Di Dier, Dominik Deppe, Torsten Diekhoff, Nele Herregods, Lennart Jans
Sacroiliitis is characterised by active and structural changes of the joint. While the Assessment of Spondyloarthritis international Society (ASAS) classification criteria stress the importance of bone marrow inflammation, recent reports suggest that osteitis can occur in various diseases, mechanical conditions and healthy individuals. Thus, structural lesions such as joint surface erosion and ankylosis
-
Magnetic resonance imaging in spondyloarthritis: Friend or Foe? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-11-11 Manouk de Hooge, Torsten Diekhoff, Denis Poddubnyy
Magnetic resonance imaging (MRI) has emerged as a valuable tool for early detection and of axial spondyloarthritis (axSpA). A standardized imaging acquisition protocol, aligned with the current state-of-the-art, is crucial to obtain MRI scans that meet the diagnostic quality requirements. It is important to note that certain lesions, particularly bone marrow edema (BME), can be induced by mechanical
-
Relapsing polychondritis: Best Practice & Clinical Rheumatology Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-10-14 Phillip Mertz, Joshua Sparks, Dale Kobrin, Sandra Amara Ogbonnaya, Ecem Sevim, Clement Michet, Laurent Arnaud, Marcela Ferrada
Relapsing polychondritis (RP) is an uncommon inflammatory disorder that predominantly targets cartilaginous structures. The disease frequently affects the nose, ears, airways, and joints, but it can also impact organs that aren't primarily cartilage-based, such as blood vessels, skin, inner ear, and eyes. Given its infrequent occurrence and recurrent symptoms, patients often experience delays in proper
-
Challenges in the diagnosis of axial spondyloarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-09-14 Floris A. van Gaalen, Martin Rudwaleit
With back pain as one of the most common complaints in the population and with no single disease feature with sufficient sensitivity and specificity to diagnose axial spondyloarthritis (axSpA) on its own, diagnosing axSpA can be challenging. In this article, we discuss clinical, laboratory, and imaging spondyloarthritis features that can be used in diagnosis and explain the general principles underlying
-
Treatment overview of axial spondyloarthritis in 2023 Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-09-05 X. Baraliakos, U. Kiltz, I. Kononenko, A. Ciurea
The treatment of patients with axial spondyloarthritis (axSpA) is characterized by non-pharmacological and pharmacological treatment options. It may depend on the type and extent of musculoskeletal and extramusculoskeletal manifestations. Recent data on non-pharmacological treatment options, such as physical activity, physiotherapy, and modification of lifestyle factors, are summarized in this review
-
The role of imaging in osteoarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-31 Eun Hae Park, Jan Fritz
Osteoarthritis is a complex whole-organ disorder that involves molecular, anatomic, and physiologic derangement. Advances in imaging techniques have expanded the role of imaging in evaluating osteoarthritis and functional changes. Radiography, magnetic resonance imaging, computed tomography (CT), and ultrasonography are commonly used imaging modalities, each with advantages and limitations in evaluating
-
Diagnostic delay in axial spondylarthritis: A lost battle? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-30 Rosemarie Barnett, Karl Gaffney, Raj Sengupta
Diagnostic delay in axial spondylarthritis (axSpA) remains an unacceptable worldwide problem; with evidence suggesting significant detrimental impact both clinically on the individual, and economically on society. There is therefore, a need for global action across various healthcare professions that come into contact with patients living, and suffering, with undiagnosed axSpA. Recent estimates of
-
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-30 Zuzanna Lukasik, Philippe Carron, Casper Webers
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and
-
VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-30 Maël Heiblig, Bhavisha Patel, Yvan Jamilloux
The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations
-
Pregnancy & neonatal outcomes in spondyloarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-29 Sinead Maguire, Anna Molto
Limited research has been conducted on the impact of spondylitis (SpA) on fertility, but some studies suggest a higher risk of subfertility in women with SpA compared to the general population. Factors associated with impaired fertility in SpA include pain, fatigue, stiffness, functional disorders, depression, anxiety, negative body image, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
-
The burden of osteoarthritis: Is it a rising problem? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-24 William J. Scheuing, Anthony M. Reginato, Mery Deeb, Sevtap Acer Kasman
The objective of this review is to provide an overview of the current status of osteoarthritis (OA) as one of the most common joint disorders worldwide. Despite being the 11th cause of disability globally, there has been an increase in the prevalence, annual incidence, and years lived with disability of OA, particularly in developed and developing countries. Erosive hand OA, which affects approximately
-
New and future therapies: Changes in the therapeutic armamentarium for SLE Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-24 Anca Askanase, Leila Khalili, Wei Tang, Philippe Mertz, Marc Scherlinger, Eden Sebbag, François Chasset, Renaud Felten, Laurent Arnaud
Following better understanding of molecular pathways involved in the pathogenesis of Systemic lupus erythematosus (SLE), pharmaceutical companies have been investigating new targeted drugs for SLE. The purpose of this scoping review is to provide an updated view of the most promising targeted therapies currently in clinical development or recently approved for SLE treatment as well as of the most promising
-
Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-23 Mariele Gatto, Roberto Depascale, Ana Luisa Stefanski, Eva Schrezenmeier, Thomas Dörner
Improved characterization of relevant pathogenic pathways in systemic lupus erythematosus (SLE) has been further delineated over the last decades. This led to the development of targeted treatments including belimumab and anifrolumab, which recently became available in clinics. Therapeutic targets in SLE encompass interferon (IFN) signaling, B-T costimulation including immune checkpoints, and increasing
-
Biomarkers for osteoarthritis: Current status and future prospects Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-22 Ali Mobasheri, Christian S. Thudium, Anne-Christine Bay-Jensen, Tazio Maleitzke, Sven Geissler, Georg N. Duda, Tobias Winkler
Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically
-
Musculoskeletal manifestations of systemic lupus erythematosus Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-22 Anastasiia Shumilova, Edward M. Vital
MSK is the most common and impactful symptom of lupus at a population level. It has a variety of different presentations, but joint swelling is often not present despite imaging-proven synovitis. Imaging with US and MRI has been shown to improve detection of inflammation and identify treatment-responsive patients. In contrast, the SLEDAI shows poor sensitivity, specificity, and responsiveness. While
-
Peripheral spondyloarthritis: What have we learned? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-19 María Ángeles Puche-Larrubia, Clementina López-Medina, Nelly Ziadé
The peripheral spondyloarthritis (pSpA) entity remains poorly defined in comparison with axial SpA and psoriatic arthritis, as the clinical symptoms have low specificity, the biological markers are virtually lacking, and dedicated randomized controlled trials in this specific indication remain scarce. In addition, clinical similarities between pSpA and psoriatic arthritis (PsA) have been described
-
Pregnancy in systemic lupus erythematosus Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-16 Dina Zucchi, Rebecca Fischer-Betz, Chiara Tani
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which frequently affects women of childbearing age. Nowadays, pregnancy is not contraindicated in cases of well-controlled disease activity, but pregnancies are still at higher risk of maternal and fetal complications compared to the general population. During pregnancy and puerperium patients are at risk of disease flare, and obstetric
-
Vasculitis in the 21st century: From prayers to progress Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-12 Tanaz A. Kermani, Aman Sharma
Abstract not available
-
Preface to practical procedures how to do Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-11 Kenneth S. O'Rourke, Mitsumasa Kishimoto
Abstract not available
-
The association between comorbidities and disease activity in spondyloarthritis – A narrative review Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-08-03 Philipp Bosch, Sizheng Steven Zhao, Elena Nikiphorou
Comorbidities, including cardiovascular disease, osteoporosis, and depression, are more prevalent in patients with spondyloarthritis (SpA) than in the general population. Clinical and laboratory markers of disease activity are associated with numerous of these comorbidities, and studies suggest that the treatment of SpA can have a positive impact on comorbidities; conversely, managing comorbidities
-
Clinical aspects and outcomes in osteoarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-29 Mehmet Tuncay Duruöz, Nuran Öz, Didem Erdem Gürsoy, Halise Hande Gezer
Osteoarthritis (OA) is the most prevalent type of arthritis worldwide, and its incidence significantly increases with age. It commonly affects the knees, hips, spine, big toes, and hands. OA can be identified through clinical examination, symptoms, and imaging methods. Its main symptoms include pain, stiffness, and limitations in joint movement. Examinations may reveal coarse crepitus, bony enlargement
-
Advanced molecular imaging in large-vessel vasculitis: Adopting FDG-PET into a clinical workflow Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-27 Mark A. Ahlman, Peter C. Grayson
The use of fluorodeoxyglucose–positron emission tomography (FDG-PET) imaging to detect vascular inflammation is increasingly common in the clinical management of patients with large-vessel vasculitis (LVV). In this review, the role of FDG-PET imaging to diagnose and monitor vascular disease activity will be detailed. Suggestions on incorporation of FDG-PET imaging into a clinical workflow will be provided
-
Arthrocentesis and soft tissue aspiration and injection Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-26 Michael Toprover, Nicole Leung, Michael H. Pillinger
Accessing a joint with a needle (arthrocentesis) to extract synovial fluid is a skill intrinsic to the rheumatologist's praxis. Joint aspirations are essential for diagnosing or excluding septic joints, are the gold standard for diagnosing acute crystal arthritis, and can provide valuable information about the nature of other forms of arthritis. In appropriate settings, injecting medications into joints
-
Seeing is believing: Smart use of musculoskeletal ultrasound in rheumatology practice Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-21 Sahil Koppikar, Pamela Diaz, Gurjit S. Kaeley, Lihi Eder
Musculoskeletal ultrasonography has become an increasingly valuable tool as a complement to the physical exam in rheumatology practice. Its point-of-care access, low cost, safety, portability, and reliability in trained hands, make this technique especially useful in patients with inflammatory arthritis. Growing evidence has demonstrated the value of musculoskeletal ultrasound in the detection of inflammatory
-
Classification and epidemiology of vasculitis: Emerging concepts Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-18 Tegwen Ecclestone, Richard A. Watts
The recent publication of the American College of Rheumatology (ACR)-European Alliance of Associations for Rheumatology (EULAR) classification criteria for large vessel vasculitis and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) has provided modern criteria for the classification of these conditions, which incorporate contemporary methods of investigation and diagnosis
-
Synovial fluid analysis: Relevance for daily clinical practice Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-08 Francesca Oliviero, Brian F. Mandell
Synovial fluid analysis can provide a prompt and definite diagnosis of crystal-induced arthritis, the most common acute inflammatory arthritis and a cause of chronic arthritis that may mimic rheumatoid, psoriatic, or peripheral spondyloarthritis. In many patients the diagnosis of gout or calcium pyrophosphate arthritis cannot be made with certainty without synovial fluid analysis. Additional information
-
Recent targets of osteoarthritis research Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-06 Po-Cheng Shih, Yung-Heng Lee, Hsi-Kai Tsou, James Cheng-Chung Wei
Osteoarthritis is one of the most common diseases and poses a significant medical burden worldwide. Currently, the diagnosis and treatment of osteoarthritis primarily rely on clinical symptoms and changes observed in radiographs or other image modalities. However, identification based on reliable biomarkers would greatly improve early diagnosis, help with precise monitoring of disease progression,
-
Advances in the maintenance of ANCA vasculitis remission Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-06 Loïc Guillevin
The maintenance treatment of ANCA-associated vasculitides (AAVs) has benefited from the results of several prospective clinical trials focusing on the evaluation of new drugs, therapeutic strategies, and adjuvant treatments. They also showed that rituximab was the most effective agent to maintain remission. However, because treatments can induce adverse events, including facilitating infections, therapeutic
-
Nailfold capillaroscopy Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-06 Vanessa Smith, Claudia Ickinger, Elvis Hysa, Marcus Snow, Tracy Frech, Alberto Sulli, Maurizio Cutolo
Nailfold capillaroscopy is a safe and well-established method for the assessment of structural alterations of the microcirculation. It is a crucial tool in the investigation and monitoring of patients presenting with Raynaud's phenomenon. Detection of the characteristic “scleroderma pattern” on capillaroscopy may indicate an underlying rheumatic disease, particularly systemic sclerosis (SSc). Herein
-
Rehabilitation interventions in osteoarthritis Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-04 Ayşe A. Küçükdeveci
The goals of the management of osteoarthritis (OA) are to relieve joint pain and stiffness, maintain or increase joint mobility and stability, improve activities and participation, and enhance quality of life. The first step in the management is to make a comprehensive holistic assessment to understand the impact of the disease on the individual. Then, an individualized management plan can be set via
-
Vascular ultrasound in rheumatology practice Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-07-05 Wolfgang A. Schmidt
Rheumatologists are increasingly using vascular ultrasound. Several guidelines now recommend ultrasound as the first diagnostic modality in giant cell arteritis (GCA). The German curriculum for rheumatology training has recently included ultrasound for the acute diagnosis of vasculitis. Recent studies have shown that ultrasound of temporal, axillary, subclavian, and vertebral arteries has sensitivities
-
Steroid sparing in vasculitis: Myth or reality? Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-06-22 Jennifer S. Hanberg, Eli M. Miloslavsky
Glucocorticoids are the cornerstone of therapy for all forms of vasculitis. However, glucocorticoid treatment carries with it the risk of glucocorticoid toxicity. Recent research efforts in vasculitis have emphasized investigation into strategies that reduce glucocorticoid exposure. These strategies include the adoption of rapid-acting steroid-sparing agents, reduced-dose glucocorticoid induction regimens
-
Deficiency of adenosine deaminase 2 (DADA2): Review Best Pract. Res. Clin. Rheumatol. (IF 5.2) Pub Date : 2023-06-15 Vikas Sharma, Prateek Deo, Aman Sharma
The deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by loss-of-function (LOF) mutations in the ADA2 gene and was first described in 2014. Initially, it was described as vasculopathy/vasculitis that mostly affected infants and young children and closely resembled polyarteritis nodosa (PAN). Skin rash and ischemic/hemorrhagic stroke are predominant symptoms. However